MicroRNA-148b-3p and MicroRNA-25-3p are overexpressed in fetuses with late-onset fetal growth restriction.

José Morales-Roselló*, José Luis García Gimenez†‡, Llucia Martínez Priego‡‡, Daymé González-Rodríguez†, Salvador Mena-Mollá†‡, Angel Maquieira Catalá‡‡‡, Gabriela Loscalzo*, Silvia Buongiorno*, Vaidile Jakaite*, Antonio José Cañada Martínez***, Alfredo Perales Marín*/**.

Institutions:
*Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
**Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
†EpiDisease SL, and Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER). Institute of Health Carlos III. Valencia, Spain.
‡Departamento de Fisiología, Universidad de Valencia, Valencia, Spain.
‡‡Servicio de Secuenciación, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad valenciana (FISABIO), Valencia, Spain.
‡‡‡Departamento de Química, Universidad Politécnica de Valencia, Valencia, Spain.
***Unidad de Bioestadística, Instituto de Investigación Sanitaria La Fe.

Corresponding author:
Prof. Dr. José Morales-Roselló
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe
Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain
Telephone: 34-607805830, E-mail: jose.morales@uv.es

Word Count: Word count: 3389, Table count: 3, Figure count: 2 (+1 supplemental figure).

Short title: miRNA and late-onset FGR
ABSTRACT

Objective: to describe a miRNA profile characteristic of late-onset growth restriction (FGR) and to investigate those pathways involved in their biochemical action.

Material and methods: In a prospective study, 25 fetuses: 16 normal and 9 with FGR (estimated fetal weight <10th centile plus cerebroplacental ratio <0.6765 MoM) were evaluated with Doppler ultrasound after 36 weeks. Afterwards, for every fetus, plasma from umbilical vein blood was collected at birth, miRNA was extracted, and full miRNA sequencing was performed. Subsequently, comparisons were done in order to obtain those miRNA that were differentially expressed.

Result: FGR fetuses expressed upregulation of two miRNA: miR-25-3p and especially miR-148b-3p, a miRNA directly involved in Schwann cell migration, neuronal plasticity and energy metabolism (p=0.0072, p=0.0013).

Conclusions: FGR fetuses express a different miRNA profile, which includes overexpression of miR-miR-25-3p and miR-148b-3p. This information might improve our understanding of the pathophysiological processes involved in late-onset FGR. Future validation and feasibility studies will be required to propose miRNAs as a valid tool in the diagnosis and management of FGR.

Key Words: Doppler ultrasound, Late-onset fetal growth restriction, Micro-RNA, miR-148b-3p, miR-25-3p, Schwann cell.
INTRODUCTION

Fetal growth restriction (FGR) occurs when a fetus fails to reach its growth potential\textsuperscript{1}. Its importance lies in its association with a higher probability of perinatal morbidity and mortality and the subsequent long-term neurologic and cardiovascular consequences in adult life\textsuperscript{2,3}. FGR comprises two varieties: early-onset FGR (<34 weeks) is less frequent and is characterized by the existence of placental disease, deceleration of fetal growth and progressive hemodynamic dysfunction, typically affecting in its onset the uterine and umbilical Doppler, while late-onset FGR (>34 weeks) is more frequent and is defined by the unbalance between fetal demands and placental supply, resulting in the detection of a characteristic low cerebroplacental ratio (CPR) regardless of the estimated fetal weight (EFW)\textsuperscript{4}. Late-onset FGR tends to be subtle. However, despite what might be thought, it is specially harmful, as it leads to frequently undiagnosed suboptimal arborization and brain underdevelopment\textsuperscript{5,6}.

Unfortunately, adverse perinatal outcome (APO) in fetuses with late-onset FGR is difficult to predict. Clinical protocols may use CPR or a combination of CPR and EFW for its identification. However, this methodology presents a poor accuracy and cannot be applied clinically yet\textsuperscript{7-9}. Hopefully, this prediction could be theoretically improved using diverse biochemical markers, a search that has become of crucial importance.

Micro-RNAs (miRNA) are small RNA sequences, on average 22 nucleotides in length\textsuperscript{11} with the ability to regulate gene expression in different organisms. Their action is mediated thought the inhibition of translation or the promotion of mRNA degradation\textsuperscript{12}. Their genes are encoded within the genome, suggesting that their transcription might be coordinated with the transcription of other genes. In summary, generation of the mature miRNA molecule involves the processing of a primary miRNA transcript in the nucleus to obtain the final product in the cell cytosol, a small single RNA strand which participates in a variety of cellular processes (development, proliferation, function and differentiation) and in the pathogenesis of many human diseases\textsuperscript{13}. miRNAs can target genes with relative specificity. To date, about to 2500 miRNA sequences are known in humans (miRBase v21)\textsuperscript{14}, and it was predicted that 30-80% of human genes may be influenced by at least one miRNA\textsuperscript{15,16}. Interestingly, recent studies have shown that miRNAs are also expressed in the placenta suggesting a potential regulatory role in its development\textsuperscript{17}. In addition, some miRNAs have been described to be hypoxia-regulated and associated with FGR\textsuperscript{18}. 
The purpose of the current study was to define a miRNA profile characteristic of late-onset FGR investigating those pathways involved in their biochemical action.

MATERIAL AND METHODS

Patient recruitment and Doppler examination

This was a prospective study of 25 fetuses attending at the public tertiary maternity of La Fe hospital (Institution Review Board and Hospital Ethics Committee permission number 2016/053). These fetuses were performed an ultrasound examination between 36 and 40 weeks which included a biometry and EFW calculation plus a Doppler evaluation of the umbilical (UA) and middle cerebral arteries (MCA) pulsatility indices (PI). The UA and MCA were recorded using color and pulse Doppler according to earlier descriptions\textsuperscript{19-20} and the CPR was calculated as the simple ratio between the MCA PI and the UA PI\textsuperscript{21}. All pregnancies were delivered in 15 days or less after the scan and only the last examination per fetus was included in the analysis. In order to adjust for the effect of the GA, EFW, and birth weight (BW) values were converted into local reference centiles\textsuperscript{22} adjusted only for fetal gender. Also, CPR values were converted into multiples of median (MoM) dividing each value by the 50th centile at each gestational age as earlier described\textsuperscript{19}. CPR medians (50th centile) were represented by the equation:

\[
\text{CPR 50th centile} = -3.814786276 + 0.36363249 \times \text{GA} - 0.005646672 \times \text{GA}^2
\]

Where GA was gestational age in weeks with decimals.

All Doppler examinations were performed by the first author (JMR), a certified teaching expert in obstetric ultrasound by the Spanish Society of Obstetrics and Gynecology, using General Electric Voluson® (E8/E6/730) ultrasound machines (General Electric Healthcare, Spain) with 2-8 MHz convex probes, during fetal quiescence, in the absence of fetal tachycardia, and keeping the insonation angle with the examined vessels as small as possible and always below 30°.

GA was determined according to the crown-rump length in the first trimester. Multiple pregnancies and those complicated by congenital fetal abnormalities or aneuploidies were excluded. Gestational characteristics including parity, number of gestations and maternal ethnicity, age, weight and height, were collected at examination, together with the indicated ultrasound parameters. Labor outcome data including BW, BW centile, mode of delivery, 5 minutes Apgar score, cord arterial pH and admission to the neonatal care unit were also collected at birth.

Ponderal and hemodynamic characteristics of the groups studied
For comparison purposes, the study included two different types of fetuses: late-onset FGR fetuses, with an abnormal EFW (<10th centile) and an abnormal CPR (<0.6765 MoM), and normal fetuses, with a normal EFW (>10th centile) and a normal CPR (>0.6765 MoM)\(^\text{19}\). Other fetuses with intermediate features (abnormal CPR with normal EFW or normal CPR with abnormal EFW) were not considered.

**Sample collection and small RNA extraction and quantification**

After birth, plasma samples from fetal umbilical vein and maternal peripheral blood were collected in EDTA tubes and centrifuged at 3500 rpm for 10-15 minutes. Once plasma was obtained, each sample was stored at \(-80^\circ\text{C}\) until small RNA extraction. While maternal plasma was stored for future research, 500 \(\mu\text{L}\) of fetal blood plasma were used to isolate cell-free total RNA (including miRNAs) using the miRNeasy Serum/Plasma kit (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol. The RNA was eluted with 25 \(\mu\text{L}\) of RNase-free water. The concentration of cell-free total RNA (including miRNAs) was quantified using NanoDrop ND 2000 UV-spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

**Library preparation and next-generation sequencing**

Small RNA libraries were generated and indexed using a modified Illumina TruSeq small RNA protocol. In this modified protocol the libraries were size selected (range 90-170pb) using Blue Pippin instrument (Sage Science, Beverly, MA, USA). A positive RNA control was included (Thermo Fisher Scientific Human Brain Total RNA catalog #AM7962). Single-end sequencing was performed on Illumina NextSeq platform on High Output 1x50pb RUN (NextSeq 500/550 High Output v2 75 cycles kit, FC-404-2005).

**Differential expression analysis**

The first step was to assess the quality of the Illumina raw sequences with the FastQC software (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Based on the results obtained, the sequence reads were trimmed to remove sequencing adapters and low-quality bases using the software Cutadapt (http://cutadapt.readthedocs.org/en/stable/). Once the data were deemed of sufficient quality, they were mapped against the human GRCh38 build reference sequence, taken from Ensembl. After that, the intersection between the aligned position of reads and the miRNA coordinates taken from miRBase v21 was performed. The alignment and quantification steps were performed using Subread and Rsubread Packages\(^\text{23,24}\).

A multi-dimensional scaling (MDS) plot was used to get a closer look at how samples were distributed according to the miRNAs expression values. MiRNAs with very low counts across all libraries provide little evidence for differential expression. We filtered...
out these miRNAs prior to further analysis. Subsequently, trimmed mean of M-values normalization method TMM normalization was performed to eliminate composition biases between libraries. We also estimated the specific dispersions per gene with a negative binomial distribution.

Groups Comparison

After miRNA was extracted and sequencing was performed, comparisons were done between the group of late-onset FGR fetuses and the group of normal fetuses (control group). As earlier indicated, late-onset FGR was considered when abnormal values of CPR plus abnormal values of BW were present. Conversely, normality was considered if both parameters were within normal range. As per local protocol, all fetuses were subsequently managed according to their progression in labor, including intrapartum fetal heart rate, which was interpreted according to the FIGO guidelines.

All study comparisons were performed using Mann Whitney test for continuous data and Fisher’s exact test for categorical data. Significance was considered with a p<0.05.

Prediction of miRNA targets and over-representation analysis

We first used DIANA-microT-CDS accessed from DIANA web server. This tool shows whether the target was also predicted by miRanda or TargetScan or was experimentally validated in TarBase v7.0. We used the DIANA-miRPath v3.0 functional analysis online suite to identify miRNAs controlling significant molecular pathways annotated on Kyoto Encyclopaedia of Genes and Genomes (KEGG), using as default parameters: experimentally supported interactions from DIANA TarBase v.7.0; a p-value threshold of 0.001; and a microT threshold of 0.8. To reduce the number of false positive miRNA targets, we applied a false discovery rate (FDR) correction to selected KEGG pathways. The algorithm used in this analysis was a one-tailed Fisher’s exact test.
RESULTS

Descriptive statistics of the study population

The study included 25 fetuses, of which 14 (56%) were male and 11 (44%) female, being all of Spanish Caucasian origin. Supplemental figure 1 shows the distribution of measurements according to the CPR MoM and BW centile\(^8,19,28\). 9 patients presented late-onset FGR (abnormal CPR plus abnormal BW values) while 16 were fetuses with normal hemodynamic and ponderal features (normal CPR plus normal BW).

In table 1 we compare normal versus FGR pregnancies. In summary, mothers in the FGR group were thinner than those in the normal group and fetuses had a lower CPR MoM, EFW, EFW centile, BW and BW centile (\(p<0.001\)). In addition, when compared with the fetuses with normal outcome, FGR fetuses were delivered earlier (\(p=0.04\)).

Identification of differentially expressed miRNAs by smallRNA-seq

Table 2 shows the initial comparison between normal and FGR fetuses regarding the differential expression analysis of up-regulated and down-regulated miRNAs. For accuracy and selection purposes, only miRNAs with the criteria of FDR < 0.05 were included. FGR fetuses showed, in comparison with normal fetuses, a total of 4 initial differentially expressed miRNAs: miR-148b-3p, miR-25-3p and miR-16-5p, which were up-regulated and miR-1910-5p, which was down regulated. miR-148b-3p presented by far the highest significance. As matter of caution, we discarded miR-16-5p due to its relation with hemolysis, which might be always present in blood samples in a minor degree\(^32,33\). Figure 1 shows the heatmap of miRNA expression profile with the miRNA selected in table 2. The cluster was done on the basis of log2 (expression level in treatment/expression level in control). Yellow shows down-regulation of miRNAs and red shows up-regulation of miRNAs in blood samples from neonatal cord.

Logarithm counts per million of reads comparison

Figure 2 shows the box and whiskers plots representing the logarithm counts per million of reads (logCPM) of those miRNA that presented significant differences: miR-148b-3p and miR-25-3p (Mann Whitney \(p<0.05\)). It is noteworthy to underline that a difference existed between the differential expression analysis of up-regulated and down-regulated miRNAs and the individual statistical analysis performed between normal and FGR fetuses concerning the Logarithm counts per million of reads. When the analysis of differential expression was done, 4 miRNAs were significant with a FDR <0.05 (table 2). However, when the logarithm counts per million of reads comparison was performed in an independent way and without considering the expression of all those miRNAs that contributed to the differential expression analysis, only miR-148b-3p and miR-25-3p
turned out to be finally statistically significant (figure 2). Therefore, only these were finally selected to explore relevant pathways related with FGR.

**Analysis of miRNA targets and biochemistry pathways in the context of FGR**

All miRNAs had a large number of potential target sites, so we explored those with relevance for FGR. Interestingly and in agreement with figure 2, miR-1910-5p did not release any pathway. Therefore, miR-16-5p and miR-1910-5p were finally removed from the analysis. In order to clarify the role of the remaining miR-148b-3p and miR-25-3p in relation with FGR, we analyzed the biochemical networks in which they participated. We carried out a DIANA-miRPath v3.0 analysis and KEGG pathway analysis to look for any significantly enriched pathway. A total of 29 pathways with an FDR below 0.05 were retrieved (table 3). Some of them related with lipid metabolism, like the biosynthesis of fatty acids\textsuperscript{31} and sphingolipids\textsuperscript{34}, crucial for neuronal tissue development, while, other related with protein processing in the endoplasmic reticulum\textsuperscript{35} or with protein metabolism, like the biosynthesis of branched chain amino acids (BBCA) Valine, leucine and isoleucine\textsuperscript{36,37}.
DISCUSSION

1-Principal findings
Analyzing circulating miRNAs from neonatal cord blood and using next-generation sequencing we found that miR-148b-3p and miR-25-3p were up-regulated in late-onset FGR fetuses. This different miRNA profile is a novel finding that might improve our understanding of late-onset growth compromise.

2-Research implications
CPR MoM has emerged as the best marker of APO at the end of pregnancy, however its accuracy as a single parameter or in association with EFW centile and other clinical parameters is not enough to obtain clinically reliable results. As a consequence, new biochemical markers are being investigated in order to obtain accurate predictions of APO and neurocognitive dysfunction.

In the recent year the focus has shifted to the miRNAs. These molecules behave as fine tuners in the regulation of gene expression and are crucial for many biological processes. A large number of the more than 1000 miRNAs discovered in humans relate with pregnancy and are produced by the placenta and the uterus in normal and pathological conditions. They exert their action locally in a paracrine fashion or distally released as exosomes in maternal blood, regulating fetal and maternal homeostasis. Moreover, several studies showed that altered expression of the miRNome in maternal circulation or in placental tissue may reflect gestational disorders, such as preeclampsia, spontaneous abortion, preterm birth, low BW, or macrosomia.

2A-Role in neuronal plasticity
miR-148b seems to have special relevance in diverse molecular mechanisms related to neuronal hypoxia, neurogenesis and neuronal metabolism and development. Particularly, miR-148b-3p up-regulation promoted Schwann cell (SC) migration, whereas silencing of miR-148b-3p inhibited SC migration in vitro. The molecular background of miR-148b-3p is in fact very interesting. It belongs to the miR-148/152 family, which includes miR-148a, miR-148b and miR-152 and is considered a placental associated miRNA, which means it is expressed ubiquitously, not only in the placenta, but also in other tissues. However, as indicated, the most interesting issue concerning its role in fetal medicine is its ability to promote the growth of SC, responsible of myelin formation. miR-148-3p plays a role in the regeneration of peripheral nerves by regulating SC migration via targeting Cullin-associated NEDD8-dissociated protein 1 (Cand1). Overexpression of miR-148-3p enhanced the migratory ability of SC, while inhibition attenuated SC migration in vitro. These effects are done at unison with other miRNAs like miR-132,
miR-210, miRNA sc-3, miR-221, and miR-222, which also increase the migratory ability of SC, and miRNA sc-8, miR-9, miR-98, miR-1, and miR-182, which diminish due ability\textsuperscript{47}. A parallelism may therefore be done between peripheral nerve repair and axonal development (arborization) in the central nervous system (CNS). A good example of this is miR-132, which apart from promoting peripheral nerve repair mediated by SC as indicated, has been found to protect the central nervous system; miR-132 controls dendritic plasticity\textsuperscript{48} and is required for normal dendrite maturation in newborn neurons\textsuperscript{49}. Therefore, miRNA-132 functions as a key activity-dependent regulator of cognition, whose expression must be maintained within a limited range to ensure normal learning and memory formation\textsuperscript{50}. In fact, miR-132 has been considered as a master regulator of neuronal health\textsuperscript{51} and its supplementation is being evaluated for the treatment of diseases like Tau-associated neurodegenerative disorders\textsuperscript{52}. Therefore, in an analogous way, miR-148b-3p might also play a role in the protection of the CNS. In theory, as brain tissue depends on myelination, miR-148b-3p might contribute to the protection of brain tissue under different circumstances, like chronic hypoxia\textsuperscript{53}.

2B-Role in energy production

The possible role of miR-148b-3p in the protection of SC might have a relationship with a number of biochemical functions. Regarding carbohydrates, miR-148b inhibits hypoxia-induced elevation of lactate production and hypoxia-induced increase of glucose consumption, therefore reducing cellular growth\textsuperscript{54}. Regarding amino-acid and proteins, 148b-3p and miR-25-3p behave as key regulators of the biosynthesis of valine, leucine and isoleucine and also regulate protein processing at the endoplasmic reticulum, being both pathways of special relevance for fetal growth during the last trimester of pregnancy\textsuperscript{35-37} and in periods of nutritional deprivation\textsuperscript{55}. Finally, regarding fatty acid metabolism, both miR-25-3p and miR-148b-3p control the biosynthesis of fatty acids and sphingolipids\textsuperscript{31,34,56}, essential molecules for stem cell differentiation morphogenesis and embryo development\textsuperscript{56} that are also related with preeclampsia and FGR\textsuperscript{57,58}.

3-Clinical implications

A practical resultant of the differential expression of miR-25-3p and miR-148b-3p in fetal blood would be the possibility to detect them also in maternal blood in order to develop clinical diagnostic tests. Hypoxia-related miRNA produced in the placenta have been detected in maternal blood\textsuperscript{59}. In this regard, If miRNAs are able to cross the placental barrier and circulate between the mother and the fetus\textsuperscript{40}, miR-148b-3p and miR-25-3p might also be detected in maternal serum and become markers of APO in an isolated or combined way, consequently improving the diagnostic accuracy of the fetus with late-
onset FGR.

4-Strengths and limitations

The strengths of this study are first its novelty, as we have been the first investigators to perform a full sequencing of all miRNA in fetal blood, and second the finding of a miRNA profile directly related with neuronal development. A shortcoming however might be the absence of validation in a different population, the paucity of follow-up and the absence of data related with neurocognitive evolution in childhood.

5-Conclusion

FGR fetuses express a different miRNA profile, which includes overexpression of miR-25-3p and especially miR-148b-3p, miRNAs related with cellular metabolism and neuronal plasticity. Future work is needed to assess the levels of miR-148b-3p and miR-25-3p in maternal serum in order to evaluate if they could improve the understanding and management of late-onset FGR, helping in the prediction of neurocognitive disability.
STATEMENTS

Acknowledgements:
We thank the midwives and the personnel of the maternity operating rooms for their contribution during the collection of blood samples.

Funding sources:
Funds were obtained from several sources: 1-iPlacenta project, European Union’s Horizon 2020 Research and Innovation Programme, MarieSkłodowska-Curie grant agreement Number 765274, 2- VLC-Biomed Grant, Universidad de Valencia & Universidad Politécnica de Valencia, 3- Clinical Study Protocol X213220 Xoma, Hospital Universitario y Politécnico La Fe, 4- Charity Run “9 km 9 meses”, Instituto de Investigación Sanitaria La Fe and Ayuntamiento de Torrente, Valencia, Spain.

Statement of ethics:
Institutional Review Board permission was obtained for this study (Reference 2016/053).

Authors’ contributions:
José Morales-Roselló designed the study, performed the ultrasound examinations and wrote the manuscript.
José Luis García Gimenez, Llucia Martinez Priego, Daymé González-Rodríguez, Salvador Mena-Mollá and Angel Maquieira Catalá made the genetic analysis, supervised the final manuscript and suggested valuable inputs to the text.
Gabriela Loscalzo, Silvia Buongiorno and Vaidile Jakaite, performed data search and made notable contributions to the final text.
Antonio José Cañada Martínez performed part of the statistical analysis.
Alfredo Perales Marín supervised the manuscript and suggested valuable inputs to the text.

Conflict of interests:
José Luis García-Giménez and Salvador Mena-Mollá own stocks in EpiDisease SL, an epigenetics company focused to the development of epigenetic biomarkers. Other authors report no conflict of interests.
REFERENCES

1. American College of Obstetricians and Gynecologists. Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013;121:1122-33.

2. Lees C, Marlow N, Arabín B, Bilardo CM, Brezinka C, Derks JB, Duvekot J, Frusca T, Diemert A, Ferrazzi E, Ganziwoort W, Hecher K, Martinelli P, Ostermayer E, Papageorghiou AT, Schlembach D, Schneider KT, Thilaganathan B, Todros T, van Wassenaer-Leemhuis A, Valcamonico A, Visser GH, Wolf H; TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013;42:400-8.

3. Yzydorczyk C, Armengaud JB, Peyter AC, Chehade H, Cachat F, Juvet C, Siddeek B, Simoncini S, Sabatier F, Dignat-George F, Mitanchez D, Simeoni U. Endothelial dysfunction in individuals born after fetal growth restriction: cardiovascular and renal consequences and preventive approaches. J Dev Orig Health Dis. 2017;8:448-464.

4. Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36:86-98.

5. Miller SL, Huppi PS, Mallard C. The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome. J Physiol. 2016;594:807-23.

6. Quezada S, Castillo-Melendez M, Walker DW, Tolcos M. Development Of The Cerebral Cortex And The Effect Of The Intrauterine Environment. J Physiol. 2018 Oct 16. doi: 10.1113/JP277151.

7. Triunfo S, Crispi F, Gratacos E, Figueras F. Prediction of delivery of small for gestational age neonates and adverse perinatal outcomes by feto-placental Doppler at 37 weeks' gestation. Ultrasound Obstet Gynecol. 2018;52:430-441.

8. Morales-Roselló J, Khalil A, Fornés-Ferrer V, Perales-Marín A. Accuracy of the fetal cerebroplacental ratio for the detection of intrapartum compromise in nonsmall fetuses. J Matern Fetal Neonatal Med. 2018 Mar 21:1-11. doi: 10.1080/14767058.2018.1450380.

9. Bligh LN, Alsolai AA, Greer RM, Kumar S. Cerebroplacental ratio thresholds measured within 2 weeks before birth and risk of Cesarean section for intrapartum fetal compromise and adverse neonatal outcome. Ultrasound Obstet Gynecol. 2018;52:340-346.

10. Bligh, L. N., Alsolai, A. A., Greer, R. M., & Kumar, S. Pre-labour screening for intrapartum fetal compromise in low risk pregnancies at term: cerebroplacental ratio and placental growth factor. Ultrasound in Obstetrics & Gynecology. 2018;52;750-756.
11. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
13. Ichihara A, Jinnin M, Yamane K, Fujisawa A, Sakai K, Masuguchi S, et al. microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 2011;165:1003-10.
14. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, Fevgas A, Dalamagas T, Hatzigeorgiou AG. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 2015;43(Database issue):D153-9.
15. Lewis, BP , Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
16. Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
17. Hayder H, O’Brien J, Nadeem U, Peng C. MicroRNAs: crucial regulators of placental development. Reproduction. 2018;155:R259-R271.
18. Mouillet JF, Chu T, Hubel CA, Nelson DM, Parks WT, Sadovsky Y. The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta. 2010;31:781-4.
19. Morales-Roselló J, Khalil A, Morlando M, Hervás-Marín D, Perales-Marín A. Doppler reference values of the fetal vertebral and middle cerebral arteries, at 19-41 weeks gestation. J Matern Fetal Neonatal Med. 2015;28:338-43.
20. Acharya G, Wilsgaard T, Berntsen GK, et al. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet Gynecol. 2005;192:937-44.
21. Baschat AA, Gembruch U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol. 2003;21:124-127.
22. Figueras F, Meler E, Iraola A, Eixarch E, Coll O, Figueras J, Francis A, Gratacos E, Gardosi J. Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol. 2008;136:20-4.
23-Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic acids research. 2013; 41, e108.
24. Liao Y, Smyth, GK, Shi W. Feature counts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923-930.
25. Robinson MD, and Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biology. 2010;11: R25.

26. Robinson MD, Smyth GK: Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics. 2008;9:321-332.

27. Robinson MD, Smyth GK. Moderated statistical tests for assessing differences in tag abundance. Bioinformatics. 2007;23:2881-2887.

28. Morales-Roselló J, Khalil A, Morlando M, Papageorghiou A, Bhide A, Thilaganathan B. Changes in fetal Doppler indices as a marker of failure to reach growth potential at term. Ultrasound Obstet Gynecol. 2014;43:303-10.

29. Ayres-de-Campos D, Spong CY, Chandraharan E; FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. Int J Gynaecol Obstet. 2015;131:13-24.

30. Vlachos IS, Zagganas K, Paraskevopoulos MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43(W1):W460-6.

31. Crawford MA. The role of essential fatty acids in neural development: implications for perinatal nutrition, Am J Clin Nutr. 1993;57: 703S-709S.

32. Shah JS, Soon PS, Marsh DJ. Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs. Janigro D, ed. PLoS ONE. 2016;11:e0153200.

33. Kirschner MB, Edelman JJ, Kao SC, Valley MP, van Zandwijk N, Reid G. The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet. 2013;4:94.

34. Olsen ASB, Færgeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 2017;7. pii: 170069.

35. Metcalf J, Wikman-Coffelt J, Yoshida T, Bernal A, Rosado A, Yoshida P, Urrusti J, Frenk S, Madrazo R, Velasco L, Morales M. Energy metabolism and protein synthesis in human leukocytes during pregnancy and in placenta related to fetal growth. Pediatrics. 1973;51:866-77.

36. Mogami H, Yura S, Itoh H, Kawamura M, Fujii T, Suzuki A, Aoe S, Ogawa Y, Sagawa N, Konishi I, Fujii S. Isocaloric high-protein diet as well as branched-chain amino acids supplemented diet partially alleviates adverse consequences of maternal undernutrition on fetal growth. Growth Horm IGF Res. 2009; 19:478-85.
supplemented diet partially alleviates adverse consequences of maternal undernutrition on fetal growth. Growth Horm IGF Res. 2009;19:478-85.

38. Morales-Roselló J, Khalil A. Fetal cerebral redistribution: a marker of compromise regardless of fetal size. Ultrasound Obstet Gynecol. 2015;46:385-8.

39. Morales-Roselló J, Khalil A, Morlando M, Bhide A, Papageorghiou A, Thilaganathan B. Poor neonatal acid-base status in term fetuses with low cerebroplacental ratio. Ultrasound Obstet Gynecol. 2015;45:156-61.

40. Khalil AA, Morales-Rosello J, Elsaddig M, Khan N, Papageorghiou A, Bhide A, Thilaganathan B. The association between fetal Doppler and admission to neonatal unit at term. Am J Obstet Gynecol. 2015;213:57.e1-7.

41. Khalil AA, Morales-Rosello J, Morlando M, Hannan H, Bhide A, Papageorghiou A, Thilaganathan B. Is fetal cerebroplacental ratio an independent predictor of intrapartum fetal compromise and neonatal unit admission? Am J Obstet Gynecol. 2015;213:54.e1-10.

42. Cai M, Kolluru GK, Ahmed A. Small Molecule, Big Prospects: MicroRNA in Pregnancy and Its Complications. J Pregnancy. 2017:6972732.

43. Barchitta M, Maugeri A, Quattrocchi A, Agrifoglio O, Agodi A. The Role of miRNAs as Biomarkers for Pregnancy Outcomes: A Comprehensive Review. International Journal of Genomics. 2017:8067972.

44. Qian T, Zhao L, Wang J, et al. miR-148b-3p promotes migration of Schwann cells by targeting cullin-associated and neddylation-dissociated 1. Neural Regeneration Research. 2016;11:1001-1005.

45. Friedrich M, Pracht K, Mashreghi MF, Jäck HM, Radbruch A, Seliger B. The role of the miR-148/-152 family in physiology and disease. Eur J Immunol. 2017;47:2026-2038.

46. Qian TM, Zhao LL, Wang J, Li P, Qin J, Liu YS, Yu B, Ding F, Gu XS, Zhou SL. miR-148b-3p promotes migration of Schwann cells by targeting cullin-associated and neddylation-dissociated 1. Neural Regen Res. 2016;11:1001-5.

47. Sohn EJ, Park HT. MicroRNA Mediated Regulation of Schwann Cell Migration and Proliferation in Peripheral Nerve Injury. Biomed Res Int. 2018;2018:8198365.

48. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, Impey S. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A. 2008;105:9093-8.

49. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci U S A. 2010;107:20382-7.
50. Hansen KF, Karelin K, Sakamoto K, Wayman GA, Impey S, Obrietan K. miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct. 2013;218:817-31.
51. Wood H. MicroRNA-132 - master regulator of neuronal health? Nat Rev Neurol. 2018;14:508-509.
52. El Fatimy R, Li S, Chen Z, Mushannen T, Gongala S, Wei Z, Balu DT, Rabinovsky R, Cantlon A, Elkhal A, Selkoe DJ, Sonntag KC, Walsh DM, Krichevsky AM. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537-555.
53. Ortega SB, Kong X, Venkataraman R, Savedra AM, Kernie SG, Stowe AM, Raman L. Perinatal chronic hypoxia induces cortical inflammation, hypomyelination, and peripheral myelin-specific T cell autoreactivity. J Leukoc Biol. 2016;99:21-9.
54. Ding X, Liu J, Liu T, Ma Z, Wen D, Zhu J. miR-148b inhibits glycolysis in gastric cancer through targeting SLC2A1. Cancer Medicine. 2017;6:1301-1310.
55. Liechty E.A., Lemons J.A. Protein Metabolism in the Fetal-Placental Unit. In: Cowett R.M. (eds) Principles of Perinatal-Neonatal Metabolism. 1991. Springer, New York, USA.
56. Guanghu Wang and Erhard Bieberich. Morphogenetic sphingolipids in stem cell differentiation and embryo development. Chapter 2. Lipidomics of Stem Cells, Stem Cell Biology and Regenerative Medicine. A. Pébay, R.C.B. Wong (eds). Springer International AG 2017.
57. Charkiewicz K, Goscik J, Blachnio-Zabielska A, et al. Sphingolipids as a new factor in the pathomechanism of preeclampsia - Mass spectrometry analysis. PLoS One. 2017;12:e0177601.
58. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol. 2004;15:2440-8.
59. Whitehead CL, Teh WT, Walker SP, Leung C, Larmour L, Tong S. Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. PLoS One. 2013;8:e78487.
Figure 1.
Heatmap with the hierarchical clustering of differentially expressed miRNAs in late-onset FGR (red) versus normal fetuses (blue) according the expression levels of miRNAs (miR-1910-5p, miR-148b-3p, miR-16-5p and miR-25-3p).
Figure 2.

Box plots representing the logarithm counts per million of reads (logCPM) of circulating miRNAs (miR-148b-3p, and miR-25-3p) in late-onset FGR fetuses compared to normal fetuses. Whiskers represent the 10th and 90th centiles.
|                          | Normal fetuses, N=16 |                          | FGR fetuses, N=9 | P-value |
|--------------------------|----------------------|--------------------------|------------------|---------|
|                          | Mean (SD)            | Median (1st, 3rd Q), range | Mean (SD)        | Median (1st, 3rd Q), range |
| Maternal age             | 33.4 (4.6)           | 33.5 (29.25, 36), 27-41   | 34.2 (5.04)      | 34 (29.5, 38.5), 27-42   | 0.73      |
| Gestations               | 1.87 (1.1)           | 2 (1, 2), 1-5             | 1.89 (1.36)      | 1 (1, 2.5), 1-5           | 0.78      |
| Parity                   | 0.62 (0.72)          | 0.5 (0, 1), 0-2           | 0.67 (0.87)      | 0 (0, 1.5), 0-2           | 0.98      |
| Maternal weight (kg)*    | 65.56 (11.35)        | 67 (53.5, 73), 52-86      | 51.7 (8.2)       | 51 (48, 55), 40-67        | 0.01      |
| Maternal Height (cm)**   | 163.8 (10.5)         | 168 (156, 171), 144-176   | 161.7 (2.5)      | 162 (160, 164), 158-165   | 0.38      |
| GA at examination (weeks)| 39.4 (1)             | 39.6 (38.7, 40.2), 36.7-40.4 | 38.3 (1.4) | 38.1 (37.0, 39.4), 36.7-40.7 | 0.08      |
| EFW hadlock-4 (g)        | 3547 (441.5)         | 3505 (3161, 4013), 2830-4246 | 2491 (456) | 2500 (2134, 2763), 1810-3373 | <0.001 |
| EFW Local Pop. Ref. centiles | 70.44 (27.2)       | 78 (47.25, 95.25), 21-99  | 7.2 (10.3)       | 4 (0.5, 11), 0-32        | <0.001 |
| CPR MoM                  | 1.56 (0.28)          | 1.49 (1.42, 1.73), 1.01-2.1 | 0.48 (0.11) | 0.51 (0.37, 0.58), 0.31-0.59 | <0.001 |
| GA at labor (weeks)      | 40.14 (1.08)         | 40.6 (39.3, 41), 37.9-41.4 | 38.75 (1.5) | 38.86 (37.4, 40.1), 36.9-41 | 0.04      |
| Interval exam-labor (days) | 5.44 (3.6)         | 4.5 (3, 8), 1-15           | 3 (2.34)        | 2 (1, 5), 0-7              | 0.87      |
| Birth weight (g)         | 3610 (467.9)         | 3500 (3320, 3823), 3000-4700 | 2381 (324.7) | 2350 (2118, 2665), 1845-2800 | <0.001 |
| BW Local Pop. Ref. centiles | 62.25 (26.3)       | 61 (37.7, 91.7), 29-100  | 1.78 (1.39)     | 2 (0.5, 3), 0-4           | <0.001 |

|                          | N (%)                |                          | N (%)          | P-value |
|--------------------------|----------------------|--------------------------|----------------|---------|
| Gender                   |                      |                          |                | 0.22    |
| Male                     | 7 (43.7%)            |                          | 7 (77.8%)      |         |
| Female                   | 9 (56.3%)            |                          | 2 (22.2%)      |         |
| BW <10th Local Pop. Ref. centiles | 0 (0%)          |                          | 9 (100%)       |         |
| Apgar 5 min <7           | 0 (0%)               |                          | 0 (0%)         |         |
| Arterial cord pH <7.20***| 3 (18.7%)           |                          | 2 (22.2%)      | 0.78    |
| Ethnicity                |                      |                          |                |         |
| Caucasian                | 16 (100%)            |                          | 9 (100%)       |         |
| Non Caucasian            | 0 (0%)               |                          | 0 (0%)         |         |
| Smokers****              | 0 (0%)               |                          | 1 (11.1%)      | -       |
| Onset of labor           |                      |                          |                | 0.93    |
| Induction of labor       | 6 (37.5%)            |                          | 8 (88.9%)      |         |
| Spontaneous onset of labor| 6 (37.5%)         |                          | 0 (0%)         |         |
| Cesarean section (abnormal CTG) | 0 (0%)          |                          | 0 (0%)         |         |
| Cesarean section (elective) | 4 (25%)            |                          | 1 (11.1%)      |         |
| Mode of delivery         |                      |                          |                | 0.95    |
| Spontaneous vaginal delivery | 9 (56.3%)        |                          | 4 (44.4%)      |         |
| Assisted vaginal delivery | 1 (6.25%)           |                          | 1 (11.1%)      |         |
Descriptive statistics of the two groups studied: normal and FGR fetuses.

Notes: FGR: fetal growth restriction, SD: standard deviation, Q: quartiles, GA: Gestational age, EFW: estimated fetal weight, MCA PI: middle cerebral artery pulsatility index, UA PI: umbilical artery pulsatility index, CPR: cerebroplacental ratio, MoM: multiples of the median, Mean UtA PI: mean uterine arteries Doppler pulsatility index, Local Pop. Ref. centiles: centiles according to local population references (Hospital Clinic de Barcelona, Spain population references), CTG: cardiotocography, SGA: small for gestational age (<p10), *data was missing in 7 and 2 patients respectively, **data was missing in 6 and 2 patients respectively, ***data was missing in 1 patient in each group, ****data was missing in 7 and 1 patients respectively.

Table 2.
Differential miRNA expression between FGR and normal fetuses.

| miRNA         | LogFC  | logCPM | F        | p-value          | FDR       |
|---------------|--------|--------|----------|------------------|-----------|
| hsa-miR-148b-3p | 2.913109 | 6.392020 | 23.88636 | 7.813586e-06    | 0.003484859 |
| hsa-miR-16-5p  | 1.639640 | 12.972890 | 18.11788 | 7.311848e-05    | 0.016305421 |
| hsa-miR-1910-5p | -4.069241 | 0.916709 | 15.22769 | 2.465907e-04    | 0.036659814 |
| hsa-miR-25-3p  | 1.339374 | 11.323960 | 14.20868 | 3.726486e-04    | 0.041550317 |

logFC: logarithm with the base of 2 of the fold change. A negative logFC value corresponds to a downregulated miRNA and a positive logFC value means that the miRNA is upregulated relative to the reference condition. logCPM: logCPM: logarithm in base 2 of the counts per million reads obtained by the miRNA; F: the value of the statistic test, FDR: p corrected value with false discovery rate.
Table 3.
Selected KEGG pathways regulated by differentially expressed miRNAs miR-25-3p and miR-148b-3p in FGR vs. normal fetuses.

| KEGG pathway                           | p-value          | Genes | miRNAs                          |
|----------------------------------------|------------------|-------|---------------------------------|
| Prion diseases                         | 7.31985499212e-15 | 5     | miR-148b-3p and miR-25-3p       |
| Fatty acid biosynthesis                 | 3.52242071263e-13 | 2     | miR-148b-3p                     |
| Oocyte meiosis                         | 1.27759516409e-05 | 31    | miR-148b-3p and miR-25-3p       |
| Cell cycle                             | 1.7071934491e-05  | 42    | miR-148b-3p and miR-25-3p       |
| Viral carcinogenesis                    | 1.7071934491e-05  | 45    | miR-148b-3p and miR-25-3p       |
| Lysine degradation                      | 3.01715187799e-05 | 14    | miR-148b-3p and miR-25-3p       |
| Estrogen signaling pathway              | 0.00028055720575  | 26    | miR-148b-3p and miR-25-3p       |
| P53 signaling pathway                   | 0.000316939071553 | 24    | miR-148b-3p and miR-25-3p       |
| FoxO signaling pathway                  | 0.000929050869461 | 37    | miR-148b-3p and miR-25-3p       |
| Protein processing in endoplasmic reticulum | 0.000929050869461 | 42    | miR-148b-3p and miR-25-3p       |
| Adherens junction                       | 0.00183745694845  | 19    | miR-148b-3p and miR-25-3p       |
| Long-term depression                    | 0.00183745694845  | 15    | miR-148b-3p and miR-25-3p       |
| Proteoglycans in cancer                 | 0.0019678042498   | 42    | miR-148b-3p and miR-25-3p       |
| Steroid biosynthesis                    | 0.00292457111324  | 4     | miR-148b-3p                     |
| Hippo signaling pathway                 | 0.00292457111324  | 34    | miR-148b-3p and miR-25-3p       |
| Valine, leucine and isoleucine biosynthesis | 0.00360593689391  | 2     | miR-25-3p                       |
| Hepatitis B                             | 0.00373563003963  | 35    | miR-148b-3p and miR-25-3p       |
| Progesterone-mediated oocyte maturation | 0.00574829839216  | 26    | miR-148b-3p and miR-25-3p       |
| cGMP-PKG signaling pathway              | 0.00675142184669  | 40    | miR-148b-3p and miR-25-3p       |
| Prostate cancer                         | 0.0079060270266   | 25    | miR-148b-3p and miR-25-3p       |
| Endometrial cancer                      | 0.0100040376492   | 15    | miR-148b-3p and miR-25-3p       |
| Non-small cell lung cancer              | 0.0100700510791   | 15    | miR-148b-3p and miR-25-3p       |
| Chronic myeloid leukemia                 | 0.0129054369882   | 21    | miR-148b-3p and miR-25-3p       |
| Sphingolipid signaling pathway          | 0.0131352576976   | 27    | miR-148b-3p and miR-25-3p       |
| Colorectal cancer                       | 0.015375047919    | 16    | miR-148b-3p and miR-25-3p       |
| Glioma                                  | 0.015375047919    | 17    | miR-148b-3p and miR-25-3p       |
| Sulfur metabolism                       | 0.0155260139399   | 2     | miR-148b-3p                     |
| Thyroid cancer                          | 0.0263000781158   | 9     | miR-148b-3p and miR-25-3p       |
| RNA degradation                         | 0.0440095764865   | 21    | miR-148b-3p and miR-25-3p       |